Astragalus membranaceus
Phase 2Small molecule
Astragalus membranaceus is one of 49 small molecule programs targeting Fatigue. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
100 competitors in Subarachnoid Hemorrhage
#DrugCompanyPhaseTrials
1Activase
RochePhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Avlosulfon
AAlmirall, S.A.
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Desferal
Alnylam PharmaceuticalsPhase 2
Primacor
SanofiPhase 2
Diamox
TevaPhase 2
Dynastat
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Subarachnoid Hemorrhage1 trial
Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
Unknown status·—·Phase 2/3·NCT03271697·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Astragalus membranaceus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details